The epigenetics company Epiqmax is now part of the Berlin-based provider of longevity solutions Moleqlar. Their product portfolio is designed to combat signs of aging at the molecular level and improve health indicators.
Epiqmax was founded in 2018 as a spin-off from LMU and specializes in proteome analysis and epigenetics. The company offers an epigenetic saliva test that provides deeper insights into how the body functions at the cellular level. In the third quarter of 2023, the biotech startup had to file for insolvency.
Maximilian Griessinger, CEO of Moleqlar, says:
“The acquisition of Epiqmax is a strategic move for Moleqlar and we look forward to welcoming their expert team and advanced technologies to our company. The integration of Epiqmax’s proteome analysis technologies will significantly expand our capabilities in the analytics and product development areas.”
Moritz Völker-Albert, CEO of the newly established Moleqlar Analytics GmbH (formerly Epiqmax), comments:
“Epiqmax looks forward to becoming part of the Moleqlar team. Our technical capabilities in proteome analysis and the quantification of histone modifications will significantly strengthen Moleqlar’s capabilities and help us harness epigenetics to sustainably improve people’s lives through advanced, personalized health solutions.”
